Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: kinase modulators - Blueprint Medicines

Next Previous
Drug Profile

Research programme: kinase modulators - Blueprint Medicines

Alternative Names: BLU 6864; BLU 9931; c-KIT D816V inhibitor - Blueprint Medicines; Fibroblast growth factor receptor 4 (FGFR4) selective inhibitor - Blueprint Medicines; Highly selective kinase drugs for specific genomically-defined cancer patients - Blueprint Medicines; Kinase inhibitors - Blueprint Medicines; KIT D816V selective inhibitor - Blueprint Medicines; NTRK inhibitors; Phosphotransferase inhibitors - Blueprint Medicines; PRKACA inhibitors - Blueprint Medicines; Protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions inhibitors; RET fusion inhibitors - Blueprint Medicines; RET inhibitors - Blueprint Medicines; TrkA inhibitors; Type 4 fibroblast growth factor receptor (FGFR4) antagonists - Blueprint Medicines

Latest Information Update: 28 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Class Small molecules
  • Mechanism of Action Advanced glycosylation end product modulators; Fusion oncogene protein inhibitors; Phosphotransferase inhibitors; Protein kinase inhibitors; Protein kinase modulators; Proto oncogene protein c-kit inhibitors; Receptor protein-tyrosine kinase antagonists; TrkA receptor antagonists; Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Gastrointestinal stromal tumours; Inborn genetic disorders; Liver cancer; Mastocytosis

Most Recent Events

  • 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA
  • 28 Apr 2019 No recent reports of development identified for research development in Inborn genetic disorders in USA
  • 28 Oct 2018 No recent reports of development identified for preclinical development in Gastrointestinal-stromal-tumours in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top